Autolus Therapeutics (AUTL) Misses Q2 EPS by 4c

Autolus Therapeutics (NASDAQ: AUTL) reported Q2 EPS of ($0.46), $0.04 worse than the analyst estimate of ($0.42).

For earnings history and earnings-related data on Autolus Therapeutics (AUTL) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Eos Energy Enterprises (EOSE) PT Lowered to $5 at B.Riley
• Nuscale Power (SMR) PT Lowered to $15 at B.Riley